Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Doumas

Showing results (61-70 of 381) with videos related to

Pageof 39
Sort By:
Circulation Research|July 4, 2014
Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom)Vasilios Papademetriou, Costas Tsioufis, Michael Doumas
Kardiologia Polska|March 29, 2021
Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Current Pharmaceutical Design|April 7, 2021
Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?Athanasios Manolis, Manolis Kallistratos, Michael Doumas
Endocrinologia, Diabetes Y Nutricion|September 9, 2022
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Cardiology|June 12, 2016
Renal Sympathetic Denervation: Hibernation or Resurrection?Vasilios Papademetriou, Michael Doumas, Costas Tsioufis
The American Journal of Cardiology|February 16, 2010
Renal sympathetic denervation and systemic hypertensionMichael Doumas, Charles Faselis, Vasilios Papademetriou
Journal of Clinical Hypertension (Greenwich, Conn.)|March 11, 2015
Screening for Primary Aldosteronism: Whom and How?Michael Doumas, Vasilios Athyros, Vasilios Papademetriou
Endocrinologia, Diabetes Y Nutricion|July 10, 2021
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Kardiologia Polska|January 26, 2021
Sclerostin and cardiovascular disease: any prognostic implications?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Journal of Hypertension|March 30, 2017
Obstructive sleep apnea, hypertension, and fibrin clot properties: a novel pathogenetic link with cardiovascular disease?Michael Doumas, Konstantinos Stavropoulos, Konstantinos Imprialos
Pageof 39

Showing results (61-70 of 381) with videos related to

Sort By:
Pageof 39
Circulation Research|July 4, 2014
Renal denervation and Symplicity HTN-3: "Dubium sapientiae initium" (doubt is the beginning of wisdom)Vasilios Papademetriou, Costas Tsioufis, Michael Doumas
Kardiologia Polska|March 29, 2021
Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Current Pharmaceutical Design|April 7, 2021
Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?Athanasios Manolis, Manolis Kallistratos, Michael Doumas
Endocrinologia, Diabetes Y Nutricion|September 9, 2022
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Cardiology|June 12, 2016
Renal Sympathetic Denervation: Hibernation or Resurrection?Vasilios Papademetriou, Michael Doumas, Costas Tsioufis
The American Journal of Cardiology|February 16, 2010
Renal sympathetic denervation and systemic hypertensionMichael Doumas, Charles Faselis, Vasilios Papademetriou
Journal of Clinical Hypertension (Greenwich, Conn.)|March 11, 2015
Screening for Primary Aldosteronism: Whom and How?Michael Doumas, Vasilios Athyros, Vasilios Papademetriou
Endocrinologia, Diabetes Y Nutricion|July 10, 2021
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Kardiologia Polska|January 26, 2021
Sclerostin and cardiovascular disease: any prognostic implications?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Journal of Hypertension|March 30, 2017
Obstructive sleep apnea, hypertension, and fibrin clot properties: a novel pathogenetic link with cardiovascular disease?Michael Doumas, Konstantinos Stavropoulos, Konstantinos Imprialos
Pageof 39